PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.79%
G&A reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
143.99%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
-60.41%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-60.41%
Both companies reducing total costs. Martin Whitman would check industry trends.
2.95%
Interest expense growth while TRVN reduces costs. John Neff would investigate differences.
-100.00%
D&A reduction while TRVN shows 6.74% growth. Joel Greenblatt would examine efficiency.
-109.95%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
62.96%
Operating income growth exceeding 1.5x TRVN's 14.24%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-184.33%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
47.99%
Pre-tax income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
387.82%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
53.00%
Net income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
52.84%
EPS growth while TRVN declines. John Neff would investigate advantages.
52.84%
Diluted EPS growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.